Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

SI - Site Forums : SI Spammer Hall of Fame -- Ignore unavailable to you. Want to Upgrade?

To: SI Ron (Crazy Music Man) who wrote (3766)	2/27/2013 4:49:55 PM
From: Ian@SI	Read Replies (1) \| Respond to of 4105

I confess that I didn't look at Allenex prior to calling it spam. I suspect it probably is spam. But it could just be a high risk speculation idea. First timer coming to the Biotech Valuation thread saying the "unknown" company is growing fast just smells like spam to me. The year over year comparisons from the company's annual report and the operating margins are not indicative of a "hot" prospect. to me, at least. Following comes from a PDF of their annual report. Original is at: allenex.com Bottom of the page - financial reports. ALLENEX AB (PUBL) YEAR- END REPORT 2012 For the fourth quarter October - December ? Net sales for the quarter amounted to SEK27.4 million (27.5). Sales were impacted by a negative currency effect of SEK1.2 million compared to the same period last year . Adjusted for currency effects, the growth rate was 4 percent. ? Operating income (EBIT) for the quarter was SEK0.6million(-76.0) , with currency effects having a negative impact of SEK 1.4 million on results compared to the same period last year . ( In 2011, earnings were impacted by impairment losses of SEK 74.6 million. ) ? Operating margin for the quarter was 2 percent. ? Earnings after tax for the quarter was SEK 0.9 million(-71.7). ? Earnings per share for the quarter, basic and diluted, were SEK0.03(-0.75). For the January - December period ? Net sales for the year amounted to SEK 112.7million(98.7) , corresponding to an increase of 14 percent compared to last year. ( Olerup GmbH became a part of the group on June 1, 2011). Sales compared to 2011 were impacted by a negative currency effect of SEK 2.3 million. ? Operating income(EBIT) for the year was SEK 7.9 million(-88.1) , with currency effects having a negative impact of SEK 3.7 million on results compared to last year . ( 2011 results were charged with impairment losses of SEK 74 .6 million . ) ? Operating margin for the year was 7 percent . ? Earnings after tax for the year was SEK 0.3 million(-504.7) . ( 2011 results were charged with i m- pairment losses of SEK 489 .3 million ) . ? Earnings per share for the year, basic and diluted, were SEK0.04(-7.23) . Si gnificant events after the year end ? The Allenex subsidiary AbSorber received an EU grant of EUR 215,000 over a three - year period ? Allenex received a breakthrough order in the U.S. for SBT Resolver™ from a leading HLA typing l a- boratory. The yearly sales value is estimated at more than SEK 2 million